½ÃÀ庸°í¼­
»óǰÄÚµå
1595146

PCR ±â¼ú ½ÃÀå : ±â¼ú, Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

PCR Technologies Market by Technique (Conventional PCR, Digital PCR, Hot-Start PCR), Product Type (Instruments, Reagents & Consumables, Software & Services), Application, End-user - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

PCR ±â¼ú ½ÃÀåÀº 2023³â¿¡ 49¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 54¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.64%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 94¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) ±â¼úÀº DNA ¿°±â¼­¿­À» ÁõÆøÇÏ´Â Áß¿äÇÑ µµ±¸·Î ÀÛ¿ëÇÏ¸ç ºÐÀÚÁø´Ü ½ÃÀå¿¡¼­ Æø³ÐÀº ¹üÀ§¸¦ Ä¿¹öÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸, ¹ýÀÇÇÐ, ÀÇ·á Áø´Ü, »ý¹°¹æ¾î µî ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß¿¡ ÇʼöÀûÀÎ PCRÀÇ Çʿ伺Àº ¼Óµµ, Á¤È®¼º, ÃÖ¼ÒÇÑÀÇ DNA »ùÇ÷ΠÀÛ¾÷ÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ °¡Àå Áß¿äÇϸç, Áúº´ °¨Áö, °³ÀÎ ¸ÂÃãÇü ÀÇ·á, À¯ÀüÀÚ ¿¬±¸¿¡ µµ¿òÀÌ µÇ´Â »ó¼¼ÇÑ À¯ÀüÀÚ ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. PCR ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â À¯Àüü ¿¬±¸ÀÇ ¹ßÀü, Àü¿°º´ÀÇ À¯Çà, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ÀÖÀ¸¸ç, ÃÖÁ¾ ¿ëµµ¿¡´Â ÀÓ»ó ½ÇÇè½Ç, º´¿ø, Çмú ±â°ü, »ý¸í °øÇÐ ±â¾÷ µîÀÌ Æ÷ÇԵ˴ϴÙ. ÃÖ±Ù Ãß¼¼´Â PCR°ú µðÁöÅÐ ¹× ÇöÀå Áø´Ü °Ë»ç¿ÍÀÇ ÅëÇÕÀ» °­Á¶ÇÏ¿© ½Å¼ÓÇÑ Áø´ÜÀ» °­È­Çϰí ÀÖÀ¸¸ç, Äڷγª19 ÆÒµ¥¹ÍÀº ¹ÙÀÌ·¯½º ½Äº°¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â PCR ±â¼úÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­ÇÏ¿© ÈÞ´ë¿ë PCR ÀåÄ¡ °³¹ß°ú °°Àº »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. âÃâÇß½À´Ï´Ù. ±×·¯³ª ³ôÀº ºñ¿ë, ±â¼úÀû º¹À⼺, Â÷¼¼´ë ½ÃÄö½Ì°ú °°Àº ´ëü ±â¼úÀÇ µîÀåÀ¸·Î ÀÎÇÑ ¾î·Á¿òµµ ÀÖ½À´Ï´Ù. PCR ±â¼úÀÇ Çõ½ÅÀº ¹Î°¨µµ ¹× ¼Óµµ Çâ»ó, ºñ¿ë Àý°¨, µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ AI ÅëÇÕ¿¡ ÃÊÁ¡À» ¸ÂÃß¾î ÀÀ¿ë ºÐ¾ß¸¦ È®´ëÇÒ ¼ö ÀÖ´Â ÀáÀçÀû ±ÔÁ¦ À庮°ú ¼÷·ÃµÈ ÀηÂÀÇ Çʿ伺ÀÌ Ãß°¡ÀûÀÎ Á¦¾à¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿©ÀüÈ÷ °æÀïÀÌ Ä¡¿­ÇÏÁö¸¸, Æ´»õ ¿ëµµ¿¡ ÁýÁßÇϰųª Á¢±Ù¼ºÀ» ³ôÀÌ´Â »ç¿ëÀÚ Ä£È­ÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇÏ¿© Á¢±Ù¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â ±âȸ¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. PCR ±â¼úÀº ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí È¿À²¼ºÀ» Çâ»ó½Ãų °ÍÀ¸·Î ±â´ëµÇ´Â ¹ßÀü°ú ÇÔ²² °è¼Ó ÁøÈ­Çϰí ÀÖÁö¸¸, ÀÌÇØ°ü°èÀÚµéÀº °æÀïÀÇ ¾Ð·Â°ú ±ÔÁ¦ ȯ°æÀ» ÇìÃijª°¡¾ß Çϸç, PCR ±â¼úÀº °è¼Ó ¹ßÀüÇϰí ÀÖÁö¸¸, ÀÌÇØ°ü°èÀÚµéÀº °æÀïÀÇ ¾Ð·Â°ú ±ÔÁ¦ ȯ°æÀ» ÇìÃijª°¡¾ß ÇÕ´Ï´Ù. ÇØ¾ß ÇÕ´Ï´Ù. Çõ½ÅÀ» ÃËÁøÇÏ´Â °ÍÀº ¸Å¿ì Áß¿äÇϸç, ÇÁ·Î¼¼½º ÀÚµ¿È­ ¹× PCR ¿ëµµÀÇ ´Ü¼øÈ­¸¦ ÅëÇØ ±× ¹üÀ§¿Í ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ÀÇ À¯¿ë¼ºÀ» È®´ëÇÏ´Â °ÍÀÌ ½ÃÀåÀÇ Ãß¼¼°¡ µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 49¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 54¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 94¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 9.64%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â PCR ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

PCR ±â¼ú ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è ÁßÁõ Áúȯ Áõ°¡
    • ¿¬±¸°³¹ß¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø
    • ¿¬±¸¿¡¼­ ½Ç½Ã°£ Á¤·®Àû PCR(RT-qPCR) ¿ëµµ Áõ°¡
    • °úÇмö»ç ºÎ¹®ÀÇ ³ôÀº Á߿伺
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • À§À½¼º ¹× Àç°¨¿° °¡´É¼º
  • ½ÃÀå ±âȸ
    • Áø´Ü¼¾ÅÍ ¹× º´¿ø ¼ö Áõ°¡
    • À¯Àüü ±â¹Ý ½Å¾à°³¹ß¿¡ ´ëÇÑ Á¢±ÙÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
    • Äڷγª19·Î ÀÎÇÑ RT-PCRÀÇ ±Þ¼ºÀå
  • ½ÃÀå °úÁ¦
    • ´ëü °Ë»ç °¡´É ¿©ºÎ
    • º¸Çè »óȯ Á¤Ã¥ÀÇ ºÎÀç

Portre's Five Forces: PCR ±â¼ú ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : PCR ±â¼ú ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼® : PCR ±â¼ú ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº PCR ±â¼ú ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® PCR ±â¼ú ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

PCR ±â¼ú ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º PCR ±â¼ú ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â PCR ±â¼ú ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PCR ±â¼ú ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ PCR ±â¼ú ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ ±×¸®´Ù.

PCR ±â¼ú ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå PCR ±â¼ú ½ÃÀå : ±â¼úº°

  • ±âÁ¸ PCR
  • µðÁöÅÐ PCR
  • ÇÖ ½ºÅ¸Æ® PCR
  • ¸ÖƼÇ÷º½º PCR
  • ½Ç½Ã°£ PCR
  • ¿ªÀü»çÁø PCR

Á¦7Àå PCR ±â¼ú ½ÃÀå : Á¦Ç° À¯Çüº°

  • ±â±â
  • ½Ã¾à ¹× ¼Ò¸ðǰ
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦8Àå PCR ±â¼ú ½ÃÀå : ¿ëµµº°

  • Áø´Ü ¿ëµµ
  • ȯ°æ ¿ëµµ
  • À¯ÀüÀÚ ¹ßÇö ºÐ¼®
  • À¯ÀüÀÚ ¹è¿­ ºÐ¼®
  • Áö³ëŸÀÌÇÎ
  • ÇÙ»ê °¨Áö
  • ÇÙ»ê ÇÕ¼º
  • Ç¥ÁØ °ËÁõ/°ËÁõ

Á¦9Àå PCR ±â¼ú ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Çмú±â°ü ¹× Á¤ºÎ±â°ü
  • ÀÀ¿ë »ê¾÷
  • ÇコÄÉ¾î ¾÷°è
  • º´¿ø ¹× Áø´Ü¼¾ÅÍ
  • Á¦¾à ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ PCR ±â¼ú ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ PCR ±â¼ú ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ PCR ±â¼ú ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Analytik Jena GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • Eppendorf SE
  • F. Hoffmann-La Roche Ltd.
  • Fluidigm Corporation by Standard BioTools Inc.
  • Merck KGaA
  • Promega Corporation
  • Qiagen N.V.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
LSH

The PCR Technologies Market was valued at USD 4.98 billion in 2023, expected to reach USD 5.43 billion in 2024, and is projected to grow at a CAGR of 9.64%, to USD 9.49 billion by 2030.

Polymerase Chain Reaction (PCR) Technologies have a broad scope within the molecular diagnostics market, serving as a crucial tool for amplifying DNA sequences. It's integral in various applications like research, forensics, medical diagnostics, and biodefense. PCR's necessity is paramount for its speed, accuracy, and capacity to work with minimal DNA samples, enabling detailed genetic analysis that aids in disease detection, personalized medicine, and genetic research. End-use includes clinical laboratories, hospitals, academic institutions, and biotech companies. Key growth factors in the PCR technology market involve advancements in genome studies, growing prevalence of infectious diseases, and escalating demand for precision medicine. Recent trends highlight the integration of PCR with digital and point-of-care testing, enhancing rapid diagnostics. The COVID-19 pandemic has accelerated PCR technology adoption due to its critical role in identifying the virus, spawning new opportunities like the development of portable PCR devices. However, challenges include high costs, technical complexities, and the advent of alternate technologies such as next-generation sequencing. Furthermore, potential regulatory hurdles and the need for skilled personnel pose added constraints. Innovations in PCR technology could focus on improving sensitivity and speed, reducing costs, and integrating AI for data analysis to expand applications. The market remains competitive but ripe for entrants focusing on niche applications or developing user-friendly, cost-efficient solutions that enhance accessibility. Strategic collaborations and investments in R&D are recommended for companies aiming to capture emerging opportunities in personalized medicine and infectious disease control. While PCR technology continues to evolve with advancements promising to streamline workflows and increase efficiency, stakeholders must navigate competitive pressures and regulatory landscapes. Fostering innovation is crucial, with a market inclination towards automating processes and simplifying PCR applications to broaden its scope and utility across diverse sectors.

KEY MARKET STATISTICS
Base Year [2023] USD 4.98 billion
Estimated Year [2024] USD 5.43 billion
Forecast Year [2030] USD 9.49 billion
CAGR (%) 9.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PCR Technologies Market

The PCR Technologies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of critical diseases across the world
    • Government support for R&D
    • Rise in Real-time Quantitative PCR (RT-qPCR) application in research
    • High importance in forensics department
  • Market Restraints
    • False negatives and reinfections possibilities
  • Market Opportunities
    • Growth in number of diagnostic centers and hospitals
    • Rising approach towards genome-based drug discovery
    • Rapid growth in RT-PCR due to COVID-19
  • Market Challenges
    • Availability of alternative test
    • Lack of supportive reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the PCR Technologies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PCR Technologies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PCR Technologies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PCR Technologies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PCR Technologies Market

A detailed market share analysis in the PCR Technologies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PCR Technologies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PCR Technologies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PCR Technologies Market

A strategic analysis of the PCR Technologies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PCR Technologies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Analytik Jena GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Eppendorf SE, F. Hoffmann-La Roche Ltd., Fluidigm Corporation by Standard BioTools Inc., Merck KGaA, Promega Corporation, Qiagen N.V., Takara Bio, Inc., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the PCR Technologies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technique, market is studied across Conventional PCR, Digital PCR, Hot-Start PCR, Multiplex PCR, Real-Time PCR, and Reverse Transcription PCR.
  • Based on Product Type, market is studied across Instruments, Reagents & Consumables, and Software & Services.
  • Based on Application, market is studied across Diagnostic Applications, Environmental Applications, Gene Expression Analysis, Genetic Sequencing, Genotyping, Nucleic Acid Detection, Nucleic Acid Synthesis, and Standard Validation/Verification.
  • Based on End-user, market is studied across Academia & Government Organizations, Applied Industries, Healthcare Industry, Hospitals & Diagnostic Centers, and Pharma-Biotech Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of critical diseases across the world
      • 5.1.1.2. Government support for R&D
      • 5.1.1.3. Rise in Real-time Quantitative PCR (RT-qPCR) application in research
      • 5.1.1.4. High importance in forensics department
    • 5.1.2. Restraints
      • 5.1.2.1. False negatives and reinfections possibilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth in number of diagnostic centers and hospitals
      • 5.1.3.2. Rising approach towards genome-based drug discovery
      • 5.1.3.3. Rapid growth in RT-PCR due to COVID-19
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative test
      • 5.1.4.2. Lack of supportive reimbursement policies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. PCR Technologies Market, by Technique

  • 6.1. Introduction
  • 6.2. Conventional PCR
  • 6.3. Digital PCR
  • 6.4. Hot-Start PCR
  • 6.5. Multiplex PCR
  • 6.6. Real-Time PCR
  • 6.7. Reverse Transcription PCR

7. PCR Technologies Market, by Product Type

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Consumables
  • 7.4. Software & Services

8. PCR Technologies Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic Applications
  • 8.3. Environmental Applications
  • 8.4. Gene Expression Analysis
  • 8.5. Genetic Sequencing
  • 8.6. Genotyping
  • 8.7. Nucleic Acid Detection
  • 8.8. Nucleic Acid Synthesis
  • 8.9. Standard Validation/Verification

9. PCR Technologies Market, by End-user

  • 9.1. Introduction
  • 9.2. Academia & Government Organizations
  • 9.3. Applied Industries
  • 9.4. Healthcare Industry
  • 9.5. Hospitals & Diagnostic Centers
  • 9.6. Pharma-Biotech Companies

10. Americas PCR Technologies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific PCR Technologies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa PCR Technologies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Analytik Jena GmbH
  • 4. Becton, Dickinson and Company
  • 5. Bio-Rad Laboratories, Inc.
  • 6. bioMerieux SA
  • 7. Danaher Corporation
  • 8. Eppendorf SE
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. Fluidigm Corporation by Standard BioTools Inc.
  • 11. Merck KGaA
  • 12. Promega Corporation
  • 13. Qiagen N.V.
  • 14. Takara Bio, Inc.
  • 15. Thermo Fisher Scientific, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦